Epsilon-aminocaproic acid and renal complications: case report and review of the literature.
Epsilon-aminocaproic acid (EACA) is a potent anti-fibrinolytic agent that is used in the treatment of excessive bleeding resulting from a systemic fibrinolytic state. It can also be used to treat hematuria through its action on decreasing urinary fibrinolysis. A broad range of renal complications has been ascribed to EACA. Although they are rare, they may be life-threatening and should therefore be immediately recognized.
Manjunath
G
G
Department of Medicine, New England Medical Center, Boston, MA 02111, USA.
Fozailoff
A
A
Mitcheson
D
D
Sarnak
M J
MJ
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D015119:Aminocaproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D006417:Hematuria; D006801:Humans; D006869:Hydronephrosis / Q000000981:diagnostic imaging / Q000209:etiology; D007668:Kidney / Q000000981:diagnostic imaging; D009403:Nephrostomy, Percutaneous; D011859:Radiography; D013927:Thrombosis / Q000188:drug therapy; D014463:Ultrasonography
D000933:Antifibrinolytic Agents; D003404:Creatinine; D015119:Aminocaproic Acid